Introduction
============

Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China and Southeast Asia that is highly invasive and has a high metastasis rate.[@b1-cmar-10-1935]--[@b4-cmar-10-1935] With the development of diagnostic imaging, radiotherapeutic techniques, and chemotherapy regimens, the ability to control NPC has improved significantly.[@b5-cmar-10-1935] However, 20%--30% of newly diagnosed, non-metastatic patients still develop local recurrence or distant metastasis after radical chemoradiotherapy.[@b6-cmar-10-1935],[@b7-cmar-10-1935] Although the tumor-node-metastasis (TNM) cancer staging system summarized by the American Joint Committee on Cancer and the International Union for Cancer Control (AJCC/UICC) provides a useful benchmark for establishing a treatment strategy and estimating the prognosis, there remain large variations in the clinical outcomes of patients with the same stage who are undergoing similar treatment strategies.[@b8-cmar-10-1935] Therefore, the staging system is based only on the anatomical extent, which is not enough to evaluate the whole tumor status or guide therapy.

Recently, a growing amount of evidence has indicated that tumor stroma cells play an important role in the carcinogenesis and progression of cancer.[@b9-cmar-10-1935]--[@b11-cmar-10-1935] Cancer-associated fibroblasts (CAFs) are primary components of tumor stroma cell populations, which are characterized by "de novo" expression of α-smooth muscle actin (α-SMA) and are known to promote the growth and invasion of cancer cells by various mechanisms, such as growth factor and chemokine production, extracellular matrix remodeling, and so on, as well as aid in the suppression of the host immune response.[@b12-cmar-10-1935]--[@b15-cmar-10-1935] Tumor-associated macrophages (TAMs) are also major stromal components within tumors that exist as a heterogeneous population of cells derived from monocytes and are polarized into two functionally distinct forms, M1 and M2, in response to tissue microenvironments and/or inflammatory status.[@b16-cmar-10-1935] CD68 has been widely used as a pan-macrophage marker in previous studies,[@b17-cmar-10-1935] and the correlations between CD68^+^ TAMs and the prognosis of patients were inconsistent among various cancers including thyroid cancer, lung cancer, hepatocellular cancer, esophageal cancer, oral squamous cell carcinoma (OSCC), and so on.[@b18-cmar-10-1935]--[@b22-cmar-10-1935] CD163 is one of the markers used to identify M2 macrophages in several tumors and has predicted adverse outcomes.[@b23-cmar-10-1935]--[@b29-cmar-10-1935] Some reports have indicated that CAFs and TAMs are synergistically associated with the prognostic significance in several types of tumors.[@b30-cmar-10-1935]--[@b32-cmar-10-1935] However, the clinical significance of TAMs and CAFs and the relationship between TAMs and CAFs in NPC has not been determined.

In this study, initially, we used triplets of tissue microarrays (TMAs), including 152 NPC specimens from patients with long follow-ups to clarify the clinical significance of TAMs and CAFs by analyzing the expression of α-SMA (fibroblasts), CD68, and CD163 and their relationship between one another. Then, we constructed a model based on these markers to predict NPC patients' prognosis, which was further validated with another TMA comprising 108 NPC specimens.

Patients and methods
====================

Patients and samples
--------------------

We performed a retrospective review of clinical records of patients with newly diagnosed, non-metastatic NPC in Sun Yat-Sen University Cancer Center (SYSUCC), and those with high-quality, formalin-fixed, paraffin-embedded NPC tissues from the original diagnostic biopsy were enrolled in the study. Two sets of TMAs including 260 specimens were analyzed in our study. TMA comprising specimens from 152 patients treated with two-dimensional radical radiotherapy (2DRT) between November 1999 and December 2000 was used as the training set, and another TMA comprising specimens from 108 patients treated with intensity-modulated radiation therapy (IMRT) between December 2010 and October 2013 was used for validation. All patients were restaged according to the 7th edition UICC/AJCC cancer staging system. This study was reviewed and approved by the institutional review board and ethics committee of SYSUCC. Informed written consents for using tissue and clinical data for scientific research were obtained from all participants in our study. TMA was constructed as described previously.[@b33-cmar-10-1935]

Immunohistochemistry (IHC)
--------------------------

Briefly, 4-µm thick tissue sections of formalin-fixed, paraffin-embedded NPC tissues were deparaffinized in xylene and rehydrated through graded alcohol. Then, antigenic retrieval was performed with sodium citrate and a high-pressure boiler for 20 minutes. After cooling down to the room temperature, the sections were incubated with 3% hydrogen peroxide for 10 minutes to inhibit endogenous peroxidases. Then, the sections were incubated with anti-CD68 (diluted 1:80; Boster, Wuhan, China), anti-CD163 (diluted 1:100; Zhongshan Golden Bridge, Beijing, China), and anti-α-SMA (diluted 1:200; Zhongshan Golden Bridge) antibodies overnight at 4°C. The primary antibodies were detected by an EnVision kit (DAKO, Carpinteria, CA, USA) according to the manufacturer's instruction.

IHC assessment
--------------

Each section was screened at low-power magnification to identify the areas with the highest staining density. The positive expression of CD68 or CD163 was defined by a granular cytoplasm or a cytoplasmic and membrane staining pattern. In addition, the positive expression of α-SMA was defined by the staining of large spindle-shaped fibroblasts around the tumor cells, and vascular-positive staining as an internal control was not classified. The expression of α-SMA, CD68, and CD163 was classified into four grades: negative (0), no staining; scant (1), a small amount of scattered staining; focal (2), concentrated stains with an irregular and non-continuous focus; and abundant (3), concentrated stains with an extensive and continuous focus; this classification system was similar to the system used in a previous study.[@b31-cmar-10-1935] Each section was scored independently by two pathologists. The average values from the two pathologists were used for further analysis.

Statistical analysis
--------------------

Chi-square tests were performed for comparisons between groups. Spearman's correlation was used to analyze the correlation between the TAM and CAF markers. Survival rates were estimated by using the Kaplan--Meier method and compared with log-rank tests. Hazard ratios (HRs) and 95% CIs were estimated by a multivariable Cox proportional hazards model. The survival duration was calculated from the first day of NPC diagnosis. The primary endpoint was overall survival (OS), which was calculated from the date of diagnosis to the date of death. The secondary endpoints were progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional failure-free survival (LRFFS).

All statistical tests were two sided, and *p*-values \<0.05 were considered to be statistically significant. All statistical analyses were performed by using SPSS version 22.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

Patient characteristics and treatment in the training set
---------------------------------------------------------

The training set included 121 males and 31 females with a median age of 48 years (range, 18--71 years). There were 4 (2.6%) patients with stage I disease, 56 (36.8%) patients with stage II disease, 54 (35.5%) patients with stage III disease, and 38 (25%) patients with stage IVA--B disease. All patients underwent 2DRT with a daily fraction of 2.0 Gy and 5 fractions per week; the radiotherapy dose ranges to the nasopharynx and neck were 60--80 Gy and 50--70 Gy, respectively. Among the 152 patients with a median followup time of 130 months (range, 5--144 months), 70 (46.1%) patients died as a result of NPC, and 5 (3.3%) patients died of a non-cancer-related disease. Thirty-two (21.1%) patients suffered from locoregional recurrence, and 33 (21.7%) patients suffered from distant metastasis. The 10-year OS, PFS, LRFFS, and DMFS rates were 48%, 55%, 76%, and 76%, respectively.

CD68, CD163, and α-SMA in NPC specimens
---------------------------------------

According to the expression levels of CD68, CD163, and α-SMA, patients were allocated into the "high" group for scores of 2--3 and the "low" group for scores of 0--1 ([Figure 1](#f1-cmar-10-1935){ref-type="fig"}). The distributions of the characteristics of the training sets within the scoring groups are summarized in [Table 1](#t1-cmar-10-1935){ref-type="table"}. There were no significant relationships among the expression levels of CD68, CD163, and α-SMA and the T stages, N stages, or clinical stages. Notably, there was a lower expression of CD68 in patients older than 50 years than in the younger patients, and patients in the group of low CD163 expression tended to not undergo chemotherapy. Spearman's correlation revealed a direct correlation between CD163^+^ TAMs and CAFs ([Table 2](#t2-cmar-10-1935){ref-type="table"}).

Survival analysis and prognostic factors in NPC patients
--------------------------------------------------------

We examined the relationships among the density of TAMs and CAFs and patient survival rates in the training set. The 10-year OS, PFS, and LRFFS rates in the CD68^high^ group (n=81) were 58%, 64%, and 83%, which were significantly higher than those of 37%, 45%, and 67% in the CD68^low^ group (n=71; *p*=0.023, *p*=0.009, and *p*=0.031), respectively. However, no significant difference in DMFS was observed between the two groups (*p*=0.142; [Figure 2](#f2-cmar-10-1935){ref-type="fig"}). In contrast, the 10-year OS, PFS, LRFFS, and DMFS rates in the CD163^high^ group (n=76) were 40%, 43%, 65%, and 69%, which were significantly lower than those of 57%, 68%, 86%, and 84% in the CD163^low^ group (n=76; *p*=0.046, *p*=0.001, *p*=0.015, and *p*=0.035), respectively ([Figure 3](#f3-cmar-10-1935){ref-type="fig"}). Moreover, the 10-year OS, PFS, and LRFFS showed no significant differences between the α-SMA^high^ group and the α-SMA^low^ group. Only the 10-year DMFS rate in the α-SMA^low^ group was significantly higher than that in the α-SMA^low^ group (83% vs 69%, *p*=0.036; [Figure 4](#f4-cmar-10-1935){ref-type="fig"}).

Then, a multivariate Cox proportional hazards model was used to discriminate the independent prognostic indicators for the OS and PFS. The expressions of CD163 and α-SMA were independent prognostic factors for the OS and PFS (all *p*\<0.05), the tumor N stage was significantly associated with PFS (*p*=0.013), and age was an independent prognostic factor for OS (*p*=0.049; [Table 3](#t3-cmar-10-1935){ref-type="table"}).

Failure risk groups based on CAF and TAM levels
-----------------------------------------------

Considering the prognostic significance of the expression of both CD163 and α-SMA, we categorized the patients into three failure risk groups based on their expression levels and compared the survival rates among the expression groups. 1) The high-risk group (high expression of both CD163 and α-SMA) included 27 (17.8%) patients; 2) the intermediate-risk group (high expression of either CD163 or α-SMA) included 96 (63.2%) patients; and 3) the low-risk group (high expression of neither CD163 nor α-SMA) included 29 (19.1%) patients. The distributions of clinical characteristics in training set according to risk groups are summarized in [Table 4](#t4-cmar-10-1935){ref-type="table"}. The 10-year OS rates for the high-, intermediate-, and low-risk groups were 33%, 52%, and 69%, respectively (*p*=0.007). The 10-year PFS rates for the three groups were 29%, 53%, and 85%, respectively (*p*\<0.001). The 10-year LRFFS rates for the three groups were 65%, 72%, and 96%, respectively (*p*=0.031). In addition, the 10-year DMFS rates were 48%, 80%, and 89%, respectively (*p*\<0.001; [Figure 5](#f5-cmar-10-1935){ref-type="fig"}). The multivariate analysis showed that the N stage and risk groups were independent prognostic factors of OS and PFS, and age was an independent prognostic factor of OS, which was also similar to previous multivariate analysis before grouping ([Table 5](#t5-cmar-10-1935){ref-type="table"}).

Validation of the CAF- and TAM-based grouping
---------------------------------------------

To confirm the prognostic significance of the failure risk grouping in patients treated with IMRT, the validation set of 108 NPC specimens were collected. All patients completed radical IMRT with a daily fraction of 2.0--2.33 Gy and 5 fractions per week; the radiotherapy dose ranges to the nasopharynx and neck were 70 and 60--66 Gy, respectively. Among the 108 patients with a median follow-up time of 59 months (range, 4--88 months), 11 (10.2%) patients died as a result of NPC, 8 (7.4%) patients suffered from locoregional recurrence, and 11 (10.2%) patients suffered from distant metastasis. The high-risk group, the intermediate-risk group, and the low-risk group included 37, 42, and 29 patients, respectively. The distributions of clinical characteristics in validation set according to risk groups are summarized in [Table 4](#t4-cmar-10-1935){ref-type="table"}. The 5-year OS rates for the three groups were 76%, 89%, and 97%, respectively (*p*=0.023). The 5-year PFS rates for the three groups were 62%, 88%, and 97%, respectively (*p*\<0.001). The 5-year LRFFS rates for the three groups were 84%, 89%, and 100%, respectively (*p*=0.044). In addition, the 5-year DMFS rates were 70%, 95%, and 97%, respectively (*p*\<0.001; [Figure 6](#f6-cmar-10-1935){ref-type="fig"}). The multivariate analysis showed that risk groups were an independent prognostic factor of OS and PFS, and age was an independent prognostic factor of OS, which was similar to the results in training set ([Table 5](#t5-cmar-10-1935){ref-type="table"}).

Discussion
==========

To our knowledge, this is the first study to combine CAF and TAM markers to evaluate the prognosis of NPC patients. This study confirmed the prognostic value of TAMs and CAFs and the obvious correlation between the density of CAFs and M2 TAMs in NPC patients.

Previous studies have reported bidirectional correlations between patient survival and macrophage levels in many malignancies. For CD68, a high density of CD68^+^ macrophages was correlated with a decreased PFS and an increased likelihood of relapse in classic Hodgkin's lymphoma[@b34-cmar-10-1935] as well as with a decreased survival in patients with breast cancer[@b35-cmar-10-1935] and advanced thyroid cancer.[@b20-cmar-10-1935] However, in other malignancies, such as non-small-cell lung cancer, esophageal squamous cell carcinoma, and colon cancer, CD68^+^ macrophage density confers a marked survival advantage.[@b36-cmar-10-1935]--[@b38-cmar-10-1935] In our study, higher expression of CD68^+^ macrophages in NPC specimens predicted better OS and PFS rates and decreased locoregional failure in the univariate Cox regression analysis. As referred above, the CD68 antibody recognizes both M1 and M2 macrophages.[@b17-cmar-10-1935] M1 macrophages, which are characterized by the high expressions of proinflammatory cytokines such as interleukin (IL)-1, IL-6, and IL-12, are potent effector cells that kill microorganisms and tumor cells.[@b39-cmar-10-1935] In contrast, M2 macrophages, which are characterized by the high expression of IL-4 and IL-10, are prominently involved in cancer initiation, progression, metastasis, angiogenesis, chemoresistance, matrix breakdown, and tumor cell motility.[@b40-cmar-10-1935],[@b41-cmar-10-1935] The prognosis related to the higher expression of CD68 may be due to larger proportion or a more active response of M1 cells in the NPC tissues. Despite the non-significant *p*-value of the CD68 density after adjustment in the multivariate Cox proportional hazards model, the protective trend for survival still exists. In addition, a study of 60 patients with NPC showed that the CD68^+^ TAM density correlated with a better prognosis.[@b42-cmar-10-1935] CD163 is a highly specific marker of M2 macrophages and has been studied in several aggressive tumors, and the increased expression of CD163 was significantly associated with a poor prognosis in various cancers.[@b23-cmar-10-1935]--[@b25-cmar-10-1935],[@b29-cmar-10-1935] In our study, higher expression of CD163 predicted worse survival in NPC patients. This result is consistent with previous studies. However, there is controversy about the role of TAMs in tumor progression and metastasis. The individual macrophage markers (ie, CD68, CD163, or CD206) did not correlate with survival in a study on NPC.[@b43-cmar-10-1935] The discrepancy may be due to the sample size and keratinizing/non-keratinizing proportions of NPC patients as a regional difference, where 77 (86%) of the 91 NPC patients had keratinization carcinoma in the Netherlands. More than 95% of the patients in endemic areas such as southern China were diagnosed with non-keratinizing carcinoma, including those in our study population comprising 260 patients.[@b44-cmar-10-1935]

Recently, CAF cross talk with cancer cells has been suggested to stimulate tumor progression by creating a favorable microenvironment for progression, invasion, and metastasis.[@b12-cmar-10-1935],[@b14-cmar-10-1935] In addition, α-SMA immunostaining of CAFs in oral tongue squamous cancer,[@b45-cmar-10-1935] esophageal squamous cell carcinoma,[@b46-cmar-10-1935] colorectal cancer,[@b47-cmar-10-1935] and breast cancer[@b48-cmar-10-1935] was related to a poorer prognosis. In our study on NPC, a high level of α-SMA expression in CAFs also predicted an adverse prognosis and influenced the OS and PFS mainly through affecting the DMFS independently from the clinical stage. However, in another study on the prognosis of CAFs in 85 NPC patients, besides a poorer prognosis, α-SMA expression in fibroblasts was closely correlated with T stage (*p*\<0.05).[@b49-cmar-10-1935] This discrepancy may be caused by three reasons. On the one hand, the staging system of the previous study was based on the 2000 World Health Organization criteria; however, all cases in our study were restaged according to the 7th edition of the UICC/AJCC cancer staging system. The differences between the two staging systems may account for this discrepancy. On the other hand, the population in the training test with 152 patients is much larger than that in the previous study, which may possess a better statistical value.

Many studies in other cancers have described the obvious correlations between the density of CAFs and M2 TAMs. A study on prostate carcinoma reported that the relationship between M2 TAMs and CAFs is reciprocal, as the M2 TAMs affect the resident tissue fibroblast-to-CAF transdifferentiation, leading to their enhanced reactivity. CAFs facilitate monocyte recruitment, macrophage differentiation, and M2 polarization, and then CAFs and M2 TAMs cooperate in promoting tumorigenesis, tumor progression, and metastasis.[@b50-cmar-10-1935] The collaboration of CAFs and M2 TAMs in facilitating tumor cell growth and invasion was also verified in bladder cancer, colorectal cancer, breast carcinoma, and neuroblastoma.[@b30-cmar-10-1935],[@b32-cmar-10-1935],[@b51-cmar-10-1935],[@b52-cmar-10-1935] In addition, in the present study on NPC, besides verifying the correlation between the densities of M2 TAMs and CAFs, we determined that the high expression of both CD163 and α-SMA in the primary tumor site results in significantly worse survival in two sets of TMA containing 260 NPC patients, which is highly consistent with previous studies.

The combination of TAM and CAF expression has been developed to predict the outcomes of various cancer patients. In a study on OSCC from Japan, intermediate CAF expression and high CD163^+^ macrophage levels were significantly correlated with a poor outcome in patients with OSCC.[@b31-cmar-10-1935] According to another study from Spain, the combination of CAF and M2 markers identified three groups of patients with clear differences in disease progression and was regarded as a decisive factor in the survival of advanced-stage patients.[@b30-cmar-10-1935] Similarly, based on the density of CD163^+^ TAMs and CAFs in the tumor stroma, both the cell types are closely related to prognosis, and failure risk groups have been categorized to predict the survival of NPC patients; this stratification is an independent prognostic factor, which may be a good supplement to the TNM classification of NPC patients to identify those with a worse prognosis and consider a more intensive treatment, such as adjuvant chemotherapy and targeted therapy, for those in the high-risk group.

Limitations
===========

There are some limitations in this study. This is a retrospective design. The patient population's clinical characteristics were diverse; therefore, an observational prospective study is necessary to validate this prognostic model. In addition, the molecular mechanism of the cross talk between CAFs/TAMs and tumor cells in NPC also needs further investigation.

Conclusion
==========

We identified the densities of CD163^+^ TAMs and CAFs as independent predictors of survival, and risk groups based on the densities of CD163^+^ TAM and CAF were independent predictors of survival, which may facilitate patient counseling and individualized treatment. A prospective study to validate this prognostic model is needed.

Availability of data and materials
==================================

The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (<http://www.researchdata.org.cn>) with the approval number RDDA2018000475.

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81472525, 81572665, 81672680); the International Cooperation Project of Science and Technology Plan of Guangdong Province (Grant Nos. 2014A050503033, 2016A050502011); the Science and Technology Plan Project of Guangdong Province (Grant No. 2013B021800141); and the Foundation of Science and Technology Bureau of Guangzhou City (Grant No. 2014Y2-00179).

**Author contributions**

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

![Representative samples of low and high expression of CD68 (**A**), CD163 (**B**), and α-SMA (**C**) in nasopharyngeal carcinoma (NPC) tissues detected by immunohistochemical staining. Blood vessels were used as internal positive controls for α-SMA. Positively stained cells were identified as brown. Scale bar, 50 µm.](cmar-10-1935Fig1){#f1-cmar-10-1935}

![Kaplan--Meier analysis of the 10-year overall survival (**A**), 10-year progression-free survival (**B**), 10-year locoregional failure-free survival (**C**), and the 10-year distant metastasis-free survival (**D**) in relation to the expression of CD68 in the training test.](cmar-10-1935Fig2){#f2-cmar-10-1935}

![Kaplan--Meier analysis of the 10-year overall survival (**A**), 10-year progression-free survival (**B**), 10-year locoregional failure-free survival (**C**), and the 10-year distant metastasis-free survival (**D**) in relation to the expression of CD163 in nasopharyngeal carcinoma tissues.](cmar-10-1935Fig3){#f3-cmar-10-1935}

![Kaplan--Meier analysis of the 10-year overall survival (**A**), 10-year progression-free survival (**B**), 10-year locoregional failure-free survival (**C**), and the 10-year distant metastasis-free survival (**D**) in relation to the expression of α-SMA in the training test.](cmar-10-1935Fig4){#f4-cmar-10-1935}

![Kaplan--Meier analysis of the 10-year overall survival (**A**), 10-year progression-free survival (**B**), 10-year locoregional failure-free survival (**C**), and the 10-year distant metastasis-free survival (**D**) in relation to the risk groups of low-risk, intermediate-risk, and high-risk patients with nasopharyngeal carcinoma in the training test.](cmar-10-1935Fig5){#f5-cmar-10-1935}

![Kaplan--Meier analysis of the 5-year overall survival (**A**), 5-year progression-free survival (**B**), 5-year locoregional failure-free survival (**C**), and the 5-year distant metastasis-free survival (**D**) in relation to the risk groups of low-risk, intermediate-risk, and high-risk patients with nasopharyngeal carcinoma in the validation test.](cmar-10-1935Fig6){#f6-cmar-10-1935}

###### 

Clinical characteristics of the 152 nasopharyngeal carcinoma patients in the training set

  Clinical parameters   No. of patients   CD68   CD163   α-SMA                               
  --------------------- ----------------- ------ ------- ------- ---- ---- ------- ---- ---- -------
  Gender                                                 0.834             0.546             0.399
   Female               31                15     16              17   14           18   13   
   Male                 121               56     65              59   62           60   61   
  Age (years)                                            0.002             0.745             0.342
   ≤50                  82                29     53              40   42           45   37   
   \>50                 70                42     28              36   34           33   37   
  T stage                                                0.870             0.620             0.446
   T1--T2               91                43     48              44   47           49   42   
   T3--T4               61                28     33              32   29           29   32   
  N stage                                                0.219             0.276             0.599
   N0--N1               110               48     62              58   52           55   55   
   N2--N3               42                23     19              18   24           23   19   
  Clinical stage                                         0.888             0.869             0.379
   I--II                63                29     34              32   31           35   28   
   III--IV              89                42     47              44   45           43   46   
  Chemotherapy                                           0.781             0.001             0.509
   No                   105               50     55              62   43           52   53   
   Yes                  47                21     26              14   33           26   21   
  Vital status                                           0.023             0.035             0.145
   Alive                77                29     48              45   32           44   33   
   Dead                 75                42     33              31   44           34   41   

###### 

Correlations among the expression levels of TAM and CAF markers in NPC patients

  IHC markers   CD68   CD163        α-SMA
  ------------- ------ ------------ ------------
  CD68                 *r*=−0.092   *r*=−0.038
                       *p*=0.258    *p*=0.644
  CD163                             *r*=−0.263
                                    *p*=0.001

**Abbreviations:** CAF, carcinoma associated fibroblasts; TAM, tumor-associated macrophages; NPC, nasopharyngeal carcinoma; IHC, immunohistochemistry; α-SMA, α-smooth muscle actin.

###### 

Multivariate Cox proportional hazards model of the training set

  Covariate        Overall survival       Progression-free survival                          
  ---------------- ---------------------- --------------------------- ---------------------- -------
  Gender                                                                                     
   Female          Reference                                          Reference              
   Male            1.234 (0.668--2.282)   0.502                       1.802 (0.876--3.709)   0.110
  Age (years)                                                                                
   ≤50             Reference                                          Reference              
   \>50            1.628 (1.002--2.644)   0.049                       1.294 (0.760--2.203)   0.343
  T stage                                                                                    
   T1--T2          Reference                                          Reference              
   T3--T4          1.760 (0.787--3.935)   0.169                       1.572 (0.674--3.666)   0.295
  N stage                                                                                    
   N0--N1          Reference                                          Reference              
   N2--N3          1.932 (0.916--4.074)   0.084                       2.809 (1.247--6.328)   0.013
  Clinical stage                                                                             
   I--II           Reference                                          Reference              
   III--IV         0.738 (0.301--1.810)   0.506                       0.709 (0.272--1.851)   0.483
  Chemotherapy                                                                               
   No              Reference                                          Reference              
   Yes             0.456 (0.456--1.423)   0.805                       0.629 (0.336--1.175)   0.146
  CD68                                                                                       
   Low             Reference                                          Reference              
   High            0.407 (0.497--1.328)   0.812                       0.777 (0.450--1.340)   0.364
  CD163                                                                                      
   Low             Reference                                          Reference              
   High            1.848 (1.114--3.064)   0.017                       2.956 (1.664--5.252)   0.001
  α-SMA                                                                                      
   Low             Reference                                          Reference              
   High            1.823 (1.126--2.951)   0.015                       2.074 (1.238--3.472)   0.006

**Abbreviation:** HR, hazard ratio.

###### 

Distribution of clinical characteristics of the whole cohort according to risk groups

  Clinical parameters   Training set (risk groups)   Validation set (risk groups)                                          
  --------------------- ---------------------------- ------------------------------ ---- ---- ------- ----- ---- ---- ---- -------
  Gender                                                                                      0.481                        0.272
   Female               31                           8                              19   4            26    10   7    9    
   Male                 121                          21                             77   23           82    27   36   19   
  Age (years)                                                                                 0.570                        0.268
   ≤50                  82                           18                             49   15           70    27   28   15   
   \>50                 70                           11                             47   12           38    10   15   13   
  T stage                                                                                     0.848                        0.670
   T1--T2               91                           17                             59   15           12    4    6    2    
   T3--T4               61                           12                             37   12           96    33   37   26   
  N stage                                                                                     0.886                        0.102
   N0--N1               110                          22                             69   19           49    17   15   17   
   N2--N3               42                           7                              27   8            59    20   28   11   
  Clinical stage                                                                              0.628                        0.692
   I--II                63                           13                             41   9            6     3    2    1    
   III--IV              89                           16                             55   18           102   34   41   27   
  Chemotherapy                                                                                0.065                        0.472
   No                   105                          25                             64   16           38    12   18   8    
   Yes                  47                           4                              32   11           70    25   25   20   
  Vital status                                                                                0.012                        0.046
   Alive                77                           21                             47   9            97    36   39   22   
   Dead                 75                           8                              49   18           11    1    4    6    

###### 

Multivariate Cox proportional hazards model of the cohort according to the risk groups

  Covariate        Training set        Validation set                                                                                      
  ---------------- ------------------- ---------------- -------------------- --------- -------------------- ------- ---------------------- -------
  Gender                                                                                                                                   
   Female          Reference                            Reference                      Reference                    Reference              
   Male            1.22 (0.66--2.26)   0.517            1.78 (0.89--3.65)    0.117     1.41 (0.35--5.68)    0.627   3.42 (0.74--15.83)     0.117
  Age (years)                                                                                                                              
   ≤50             Reference                            Reference                      Reference                    Reference              
   \>50            1.68 (1.04--2.70)   0.033            1.33 (0.79--2.24)    0.290     5.99 (1.50--23.87)   0.011   1.93 (0.67--5.62)      0.23
  T stage                                                                                                                                  
   T1--T2          Reference                            Reference                      --                   --      --                     --
   T3--T4          1.90 (0.86--4.19)   0.113            1.72 (0.75--3.95)    0.202     --                   --      --                     --
  N stage                                                                                                                                  
   N0--N1          Reference                            Reference                      Reference                    Reference              
   N2--N3          2.08 (1.01--4.28)   0.047            3.07 (1.41--6.68)    0.005     3.17 (0.82--12.29)   0.096   2.05 (0.68--6.21)      0.206
  Clinical stage                                                                                                                           
   I--II           Reference                            Reference                      --                   --      --                     --
   III--IV         0.70 (0.29--1.70)   0.430            0.67 (0.26--1.71)    0.404     --                   --      --                     --
  Chemotherapy                                                                                                                             
   No              Reference                            Reference                      Reference                    Reference              
   Yes             0.78 (0.45--1.36)   0.385            0.64 (0.34--1.19)    0.150     1.81 (0.44--7.42)    0.411   2.93 (0.78--10.99)     0.111
  Risk group                                                                                                                               
   Low             Reference                            Reference                      Reference                    Reference              
   Intermediate    2.25 (1.05--4.82)   0.037            4.08 (1.44--11.55)   0.008     2.90 (0.31--26.98)   0.351   4.86 (0.56--42.59)     0.153
   High            3.85 (1.64--9.04)   0.002            8.70 (2.89--26.15)   \<0.001   9.63 (1.07--87.06)   0.044   21.23 (2.62--171.94)   0.004

**Abbreviation:** HR, hazard ratio.

[^1]: These authors contributed equally to this work
